BioSpace News Archive

A recent report on the global fragment based drug discovery market studied by Transparency Market Research elaborates the factors that indicates the growth of the market in coming years.

Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.

Skanska has signed a contract with the New York City Health and Hospital Corporation to renovate the North Central Bronx Hospital in Bronx, New York, USA.

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, announced positive results from a PXL770 four-week placebo-controlled PK/PD study in 16 likely-NASH patients with insulin resistance.

Net result: MSEK 23.2 (-26.8), whereof third quarter MSEK -7.2 (-7.9). The increase compared to previous year is a one-off effect due to a payment of corresponding MSEK 48.0 from the previous GAD65 manufacturer as support for transition of the manufacturing process.

Positive initial data from first Affimer-based rapid test strips for SARS-COV-2 spike protein

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced its corporate headquarters and manufacturing facility in Acton, MA, will be powered by solar-based, renewable energy beginning this week.

ProMIS Neurosciences, Inc. announces that the Board of Directors of the Corporation have considered current COVID-19 public health restrictions and determined it to be in the best interests of the Corporation and its shareholders to adjourn the Corporation’s annual meeting of shareholders to 9:00 a.m. onJuly 29, 2020 and to change the location of the AGM to Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia.

Applied Genetic Technologies Corporation announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted on June 5.

Biohaven Pharmaceutical Holding Company Ltd. reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder.